Publications en collaboration avec des chercheurs de Centro de Investigación Médica Aplicada (39)

2024

  1. Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates

    Gut

2023

  1. A novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer

    Frontiers in Immunology, Vol. 14

  2. Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates

    Brain : a journal of neurology, Vol. 146, Núm. 12, pp. 5000-5014

  3. Nutritional Interventions with Bacillus coagulans Improved Glucose Metabolism and Hyperinsulinemia in Mice with Acute Intermittent Porphyria

    International Journal of Molecular Sciences, Vol. 24, Núm. 15

  4. TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory

    Cancer Cell, Vol. 41, Núm. 11, pp. 1911-1926.e8

2022

  1. A new animal model of atrophy–hypertrophy complex and liver damage following Yttrium-90 lobar selective internal radiation therapy in rabbits

    Scientific Reports, Vol. 12, Núm. 1

  2. High value of 64Cu as a tool to evaluate the restoration of physiological copper excretion after gene therapy in Wilson's disease

    Molecular Therapy - Methods and Clinical Development, Vol. 26, pp. 98-106

2021

  1. Glucocerebrosidase gene therapy induces alpha-synuclein clearance and neuroprotection of midbrain dopaminergic neurons in mice and macaques

    International Journal of Molecular Sciences, Vol. 22, Núm. 9

  2. mRNA-based therapy in a rabbit model of variegate porphyria offers new insights into the pathogenesis of acute attacks

    Molecular Therapy - Nucleic Acids, Vol. 25, pp. 207-219

2020

  1. Id1 and pd-1 combined blockade impairs tumor growth and survival of KRAS-mutant lung cancer by stimulating PD-l1 expression and tumor infiltrating CD8+ T cells

    Cancers, Vol. 12, Núm. 11, pp. 1-22

  2. In vivo efficacy of bevacizumab-loaded albumin nanoparticles in the treatment of colorectal cancer

    Drug Delivery and Translational Research, Vol. 10, Núm. 3, pp. 635-645

2019

  1. Inhibitor of differentiation-1 sustains mutant KRAS-driven progression, maintenance, and metastasis of lung adenocarcinoma via regulation of a FOSL1 network

    Cancer Research, Vol. 79, Núm. 3, pp. 625-638

  2. Preclinical safety of topically administered nanostructure lipid carriers (NLC) for wound healing application: biodistribution and toxicity studies

    International Journal of Pharmaceutics, Vol. 569

2018

  1. Assessment of metabolic patterns and new antitumoral treatment in osteosarcoma xenograft models by [ 18 F]FDG and sodium [ 18 F]fluoride PET

    BMC Cancer, Vol. 18, Núm. 1

2017

  1. Lessons from 11C-dihydrotetrabenazine imaging in a xenograft mouse model of rat insulinoma: Is PET imaging of pancreatic beta cell mass feasible?

    Quarterly Journal of Nuclear Medicine and Molecular Imaging, Vol. 61, Núm. 4, pp. 447-455

  2. Non-invasive in vivo imaging of cardiac stem/progenitor cell biodistribution and retention after intracoronary and intramyocardial delivery in a swine model of chronic ischemia reperfusion injury

    Journal of Translational Medicine, Vol. 15, Núm. 1

  3. The inhibitor of differentiation-1 (Id1) enables lung cancer liver colonization through activation of an EMT program in tumor cells and establishment of the pre-metastatic niche

    Cancer Letters, Vol. 402, pp. 43-51

2016

  1. Glucose metabolism during fasting is altered in experimental porphobilinogen deaminase deficiency

    Human Molecular Genetics, Vol. 25, Núm. 7, pp. 1318-1327

2015

  1. Functional MMP-10 is required for efficient tissue repair after experimental hind limb ischemia

    FASEB Journal, Vol. 29, Núm. 3, pp. 960-972

  2. Infiltration of plasma rich in growth factors enhances in vivo angiogenesis and improves reperfusion and tissue remodeling after severe hind limb ischemia

    Journal of Controlled Release, Vol. 202, pp. 31-39